[12] Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in the treatment of Diabetic Dyslipidemia under brand name "Lipaglyn".

[13] In 2020, Zydus Cadila's drug Desidustat received approval by the USFDA to initiate clinical trials on cancer patients.

[17] Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbuvir, distributed under the brand name SoviHep).

[19][20][21] On 20 August 2021, DCGI granted emergency use approval of ZyCoV-D.[22] Cadila is also among the several Indian pharma companies that received the licensing agreements from the Gilead Sciences to produce remdesivir.

[24] A Mint investigative report in 2021 claimed that Zydus Lifesciences supplied possibly bacteria-contaminated batches of remdesivir to hospitals in Uttar Pradesh, Rajasthan, Maharashtra, Gujarat and Bihar, allegedly making hundreds of already sick COVID-19 patients even sicker.

[medical citation needed] Zydus was manufacturing the remdesivir in their Gujarat factory under license from United States' Gilead Sciences.